PRESS RELEASE published on 04/05/2024 at 10:17, 2 years 4 months ago APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast APONTIS PHARMA partners with Novartis for asthma medications distribution and marketing, raising forecast for 2024 financial year Distribution Agreement APONTIS PHARMA Asthma Medications Novartis Forecast Increase
BRIEF published on 04/05/2024 at 10:15, 2 years 4 months ago APONTIS PHARMA AG Enhances Forecast Following Agreement with Novartis APONTIS PHARMA AG Financial Growth Forecast Upgrade Novartis Agreement Asthma Medications
BRIEF published on 04/05/2024 at 10:15, 2 years 4 months ago APONTIS PHARMA AG améliore ses prévisions suite à un accord avec Novartis Croissance Financière APONTIS PHARMA AG Mise À Niveau Des Prévisions Accord Novartis Médicaments Contre L'asthme
PRESS RELEASE published on 04/05/2024 at 10:10, 2 years 4 months ago EQS-Adhoc: APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications APONTIS PHARMA AG raises forecast following agreement with Novartis for asthma medications Forecast Raise Financial Outlook APONTIS PHARMA AG Novartis Agreement Asthma Medications
BRIEF published on 03/28/2024 at 07:35, 2 years 5 months ago APONTIS PHARMA Anticipates Profitable Growth in 2024 After Restructuring APONTIS PHARMA Single Pill Combinations Financial Results 2023 Profitable Growth 2024 Restructuring Program
BRIEF published on 03/28/2024 at 07:35, 2 years 5 months ago APONTIS PHARMA prévoit une croissance rentable en 2024 après sa restructuration Résultats Financiers 2023 PHARMA APONTIS Croissance Rentable 2024 Combinaisons De Pilules Uniques Programme De Restructuration
PRESS RELEASE published on 03/28/2024 at 07:30, 2 years 5 months ago APONTIS PHARMA expects profitable growth again in 2024 APONTIS PHARMA expects profitable growth in 2024 with sales forecasted to rise to EUR 41.7 million and positive EBITDA of EUR 1.8 million. Performance and efficiency improvements drive future growth EBITDA Profitable Growth APONTIS PHARMA Sales Forecast Efficiency Improvements
PRESS RELEASE published on 02/09/2024 at 10:52, 2 years 6 months ago Original-Research: APONTIS PHARMA AG (von Montega AG): Kaufen APONTIS PHARMA AG hat ein Strategie-Update gegeben und finanzielle Details aus der Restrukturierung bekannt gegeben, was zu einer Reduktion der Break Even-Schwelle führt APONTIS PHARMA AG Strategie-Update Restrukturierung Finanzielle Details Break Even-Schwelle
PRESS RELEASE published on 02/06/2024 at 07:30, 2 years 6 months ago APONTIS PHARMA successfully completes performance and efficiency improvement program APONTIS PHARMA successfully completes performance and efficiency improvement program, reducing headcount and expenses. New go-to-market approach for Single Pill combinations to start on 1 March 2024 Pharmaceutical Company Efficiency APONTIS PHARMA Performance Improvement Single Pill Combinations
PRESS RELEASE published on 11/09/2023 at 07:30, 2 years 9 months ago APONTIS PHARMA presents details of the restructuring and efficiency program – Nine-month figures for 2023 and new sales and earnings forecast for 2023 published
Published on 08/29/2026 at 05:15, 2 hours 51 minutes ago Norsemont Announces Restatement of Financial Statements
Published on 08/29/2026 at 03:20, 4 hours 46 minutes ago BEACN Announces Financial Results for the Second Quarter of 2026
Published on 08/29/2026 at 01:15, 6 hours 51 minutes ago Gamma Resources Announces Increase in Private Placement to $1,750,000 and Closing of First Tranche at $872,500
Published on 08/29/2026 at 01:00, 7 hours 6 minutes ago Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement
Published on 08/28/2026 at 23:00, 9 hours 6 minutes ago Guanajuato Silver Grants Stock Options to Officer
Published on 08/29/2026 at 04:05, 4 hours ago INTCO Medical Reports 40.6% H1 2026 Revenue Growth, Expands World's Largest Disposable Glove Capacity to 107 Billion Pieces
Published on 08/28/2026 at 20:49, 11 hours 16 minutes ago Publication pursuant to Article 5(1)(b) and (3) of Regulation (EU) No. 596/2014 and Article 2(2) and (3) of the Commission Delegated Regulation (EU) No. 2016/1052 - Final Announcement
Published on 08/28/2026 at 20:42, 11 hours 23 minutes ago Aroundtown SA: Release of a capital market information
Published on 08/28/2026 at 19:10, 12 hours 55 minutes ago Invitation to Professional or Qualified Investors holding Notes to submit offers for Branicks Bridge Notes and VIB Bridge Notes
Published on 08/28/2026 at 18:01, 14 hours 4 minutes ago CPI Europe announces unaudited results for the first half of 2026
